Brief: Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV
14/02/2024 12:20
Feb 14 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES RECEIVES PRE-IND FEEDBACK FROM US
FDA FOR
PBGENE-HBV AS IT ADVANCES TOWARDS CLINICAL READINESS
* PRECISION BIOSCIENCES INC - REGULATORY FEEDBACK AND
ALIGNMENT
FROM BOTH U.S. AND EX-U.S. REGULATORS SUPPORTS CLINICAL
DEVELOPMENT PATH FOR PBGENE-HBV
* PRECISION BIOSCIENCES - IND/CTA ENABLING STUDIES WITH
FINAL
CLINICAL CANDIDATE UNDERWAY FOR PBGENE-HBV PROGRAM; EXPECT TO
FILE IND AND/OR CTA IN 2024
Source text for Eikon: ID:nBw6b8pyba
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing